Context Somatostatin analogues are commonly used to relieve symptoms in malignant
bowel obstruction (MBO) but are more expensive than other antisecretory agents. Objectives …

Context Does octreotide reduce vomiting in cancer-associated bowel obstruction?
Objectives To evaluate the net effect of adding octreotide or placebo to standardized …

Objective In patients with advanced cancer, malignant bowel obstruction (MBO) causes
gastrointestinal symptoms such as nausea and vomiting leading to severely impaired oral …

Background Malignant bowel obstruction (MBO) is a frequent complication in patients with
advanced cancer, particularly colon or gynecological malignancies. MASCC previously …

Malignant bowel obstruction is a common complication in patients with advanced abdominal
or pelvic cancer. Whereas surgery should be considered in all cases of malignant bowel …

Context Malignant bowel obstruction impairs the quality of life in patients with advanced
cancer. Octreotide, acid-suppressing medications such as H 2-receptor antagonists (H 2 …

Vomiting due to malignant intestinal obstruction is an unpleasant terminal event in many
cancer patients, which responds poorly to conventional therapies. Somatostatin and its long …

The use of symptomatic agents has greatly improved the medical treatment of advanced
cancer patients with inoperable bowel obstruction. A systematic review of studies of the most …

In advanced cancer patients with inoperable bowel obstruction, the administration of
antisecretive and antiemetic drugs has proved to be effective in controlling gastrointestinal …

Background This analysis aims to evaluate health-related quality of life (HrQoL)(primary
outcome for this analysis), nausea and vomiting, and pain in patients with inoperable …